We thank Drs Lehmann and Bonig for their comments on our apheresis algorithm. We are
encouraged to hear of the early external validation of our web application, including
in pediatric populations.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment.in: Kröger N Gribben J Chabannon C Yakoub-Agha I Einsele H EBMT/EHACAR-T cell handbook : Chapter 6. Springer, Cham2022: 31-35
Article info
Publication history
Published online: May 01, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Predicting chimeric antigen receptor apheresis process volumeCytotherapy
- PreviewThe recent work by O'Reilly et al. [1] provides an elegant tool for chimeric antigen receptor (CAR)–T-cell apheresis planning by generating a formula that predicts the process volume required to achieve a certain target dose of T cells. The formula is mathematically much more sophisticated than the referenced one that we had previously proposed. Our “formula” is solely the estimate that at least 40% of T cells presented at the connector will be collected into the product bag [2]. O'Reilly et al.
- Full-Text
- Preview
